Sophiris Bio

SPHS NASDAQ
0.8200
-0.0200
-2.38%
已收盘, 16:53 06/24 EDT
开盘
0.8500
昨收
0.8400
最高
0.8800
最低
0.7701
成交量
22.21万
成交均量(3M)
14.12万
52周最高
3.490
52周最低
0.7100
换手率
0.74%
市值
2,477.81万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Sophiris Bio SPHS股票价格,Sophiris Bio股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Sophiris Bio Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing products for the treatment of urological diseases. The Company is developing topsalysin (PRX302) as a treatment for the lower urinary tract symptoms of benign prostatic hyperplasia (BPH) commonly referred to as an enlarged prostate and as a treatment for localized low to intermediate risk prostate cancer. Topsalysin, a genetically modified recombinant protein, is delivered through ultrasound-guided injection directly into the prostate. This membrane-disrupting protein is selectively activated by enzymatically active prostate specific antigen (PSA), which is only present in the prostate, leading to localized cell death and tissue disruption without damage to neighboring tissue and nerves. This method of administration limits the circulation of the drug in the body. The Company has completed Phase III clinical trials of topsalysin.
展开 >

最近浏览

名称
价格
涨跌幅